JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 32 No. 9 1655-1660
© 1991 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ichiya, Y.
Right arrow Articles by Masuda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichiya, Y.
Right arrow Articles by Masuda, K.

Assessment of Response to Cancer Therapy Using Fluorine-18-Fluorodeoxyglucose and Positron Emission Tomography

Yuichi Ichiya, Yasuo Kuwabara, Makoto Otsuka, Takashi Tahara, Tomonori Yoshikai, Toshimitsu Fukumura, Ken'ichi Jingu and Kouji Masuda

Department of Radiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Correspondence: For reprints contact: Yuichi Ichiya, MD, Department of Radiology, Faculty of Medicine, Kyushu University, Maidashi, Higashi-ku, Fukuoka, 812 Japan.

ABSTRACT

In order to evaluate the usefulness of 18F-FDG PET in the assessment of therapeutic effects, FDG-PET studies were performed both before and after therapy in 26 patients with miscellaneous malignant tumors. The change in FDG uptake by therapy was compared with the change in tumor size and prognosis. All 26 lesions had a high FDG uptake before therapy. Five of seven lesions which had a relatively low FDG uptake before therapy showed no change or increase in tumor size by therapy. The decreased FDG uptake after therapy was more prominent in the partial response group than in the no change group. FDG uptake before therapy in the non-relapse group was higher than that in the relapse group. However, a decreased FDG uptake did not necessarily indicate a good prognosis. One patient with no change in tumor size and a decreased FDG uptake had no recurrence. This suggests that FDG-PET has a complementary role in the assessment of therapeutic effects.




This article has been cited by other articles:


Home page
JNMHome page
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med., January 1, 2006; 47(1): 14 - 22.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Westerterp, H. L. van Westreenen, J. B. Reitsma, O. S. Hoekstra, J. Stoker, P. Fockens, P. L. Jager, B. L. F. Van Eck-Smit, J. T. M. Plukker, J. J. B. van Lanschot, et al.
Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy--Systematic Review
Radiology, September 1, 2005; 236(3): 841 - 851.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
M. B. Fukui, T. M. Blodgett, C. H. Snyderman, J. J. Johnson, E. N. Myers, D. W. Townsend, and C. C. Meltzer
Combined PET-CT in the Head and Neck: Part 2. Diagnostic Uses and Pitfalls of Oncologic Imaging
RadioGraphics, July 1, 2005; 25(4): 913 - 930.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
Y. W. Choi, R. F. Munden, J. J. Erasmus, K. Joo Park, W. K. Chung, S. C. Jeon, and C.-K. Park
Effects of Radiation Therapy on the Lung: Radiologic Appearances and Differential Diagnosis
RadioGraphics, July 1, 2004; 24(4): 985 - 997.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. Brenner, K. H. Bohuslavizki, and J. F. Eary
PET Imaging of Osteosarcoma
J. Nucl. Med., June 1, 2003; 44(6): 930 - 942.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru
Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer
J. Nucl. Med., May 1, 2003; 44(5): 690 - 699.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Spence, M. Muzi, M. M. Graham, F. O'Sullivan, J. M. Link, T. K. Lewellen, B. Lewellen, S. D. Freeman, D. A. Mankoff, J. F. Eary, et al.
2-[18F]Fluoro-2-deoxyglucose and Glucose Uptake in Malignant Gliomas before and after Radiotherapy: Correlation with Outcome
Clin. Cancer Res., April 1, 2002; 8(4): 971 - 979.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Schulte, D. Brecht-Krauss, B. Heymer, A. Guhlmann, E. Hartwig, M. R. Sarkar, C. G. Diederichs, A. V. Baer, J. Kotzerke, and S. N. Reske
Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET
J. Nucl. Med., October 1, 2000; 41(10): 1695 - 1701.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al.
Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
W. Wang, H. Macapinlac, S. M. Larson, S. D. J. Yeh, T. Akhurst, R. D. Finn, J. Rosai, and R. J. Robbins
[18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2291 - 2302.
[Abstract] [Full Text]


Home page
RadiologyHome page
Y. Sugawara, K. R. Zasadny, H. B. Grossman, I. R. Francis, M. F. Clarke, and R. L. Wahl
Germ Cell Tumor: Differentiation of Viable Tumor, Mature Teratoma, and Necrotic Tissue with FDG PET and Kinetic Modeling
Radiology, April 1, 1999; 211(1): 249 - 256.
[Abstract] [Full Text]


Home page
Am. J. Neuroradiol.Home page
A. T. Ahuja, S. S. Y. Ho, S. F. Leung, J. Kew, and C. Metreweli
Metastatic Adenopathy from Nasopharyngeal Carcinoma: Successful Response to Radiation Therapy Assessed by Color Duplex Sonography
AJNR Am. J. Neuroradiol., January 1, 1999; 20(1): 151 - 156.
[Abstract] [Full Text]


Home page
ThoraxHome page
V. J Lowe and K. S Naunheim
Current role of positron emission tomography in thoracic oncology
Thorax, August 1, 1998; 53(8): 703 - 712.
[Full Text]


Home page
BloodHome page
W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al.
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose
Blood, June 15, 1998; 91(12): 4464 - 4471.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
V. J. Lowe and K. S. Naunheim
Positron Emission Tomography in Lung Cancer
Ann. Thorac. Surg., June 1, 1998; 65(6): 1821 - 1829.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Carr, S. F. Barrington, B. Madan, M. J. O'Doherty, C. A.B. Saunders, J. van der Walt, and A. R. Timothy
Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography
Blood, May 1, 1998; 91(9): 3340 - 3346.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1991 by the Society of Nuclear Medicine.